Related Experiment Video
Updated: Jun 30, 2026
A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
Published on: July 16, 2016
4-Methylumbelliferone for type 1 diabetes therapy: evidence for β-cell protection via EGFR/PI3K/Akt signaling
Shuo Yang1, Shanshan Zhu1, Xinwen Yu1
1Department of Endocrinology, Tangdu Hospital, Air Force Medical University, Xi'an, 710038, Shaanxi Province, P. R. China.
Purpose:
Type 1 diabetes mellitus (T1DM) results from autoimmune-mediated destruction of pancreatic β-cells, leading to absolute insulin deficiency. Current treatments rely on insulin replacement and do not prevent β-cell loss. 4-Methylumbelliferone (4-MU), an inhibitor of hyaluronan synthesis, has shown anti-inflammatory and cytoprotective effects, but its therapeutic potential and mechanisms in T1DM remain unclear.
Methods:
A streptozotocin (STZ)-induced mouse model of T1DM was treated with 4-MU for three weeks. Blood glucose levels and glucose tolerance were evaluated. Pancreatic islet morphology and cell composition were assessed by immunofluorescence. In parallel, STZ -injured MIN6 and βTC6 β-cells were used to investigate the effects of 4-MU on cell viability, oxidative stress, intracellular Ca²⁺ homeostasis, and glucose-stimulated insulin secretion. Network pharmacology, molecular docking, qPCR, and Western blot analyses were conducted to explore the underlying mechanisms.
Results:
4-MU significantly reduced hyperglycemia and improved glucose tolerance in T1DM mice, accompanied by preservation of β-cell mass, normalization of the β/α-cell ratio, and reduced islet inflammation. In vitro, 4-MU protected β-cells from STZ-induced injury by decreasing reactive oxygen species (ROS) accumulation, restoring intracellular Ca²⁺ balance, and improving insulin secretion. Network pharmacology identified 48 shared targets between 4-MU and T1DM, with KEGG pathway enrichment highlighting the PI3K/Akt signaling pathway. Molecular docking revealed stable binding of 4-MU to key regulators, including EGFR, Akt, ESR1, INSR, and IGF1R. Consistently, 4-MU enhanced the phosphorylation of EGFR, PI3K, and Akt in injured β-cells.
Conclusion:
4-MU exerts protective effects in T1DM by preserving pancreatic β-cells survival and function, potentially through activation of the EGFR/PI3K/Akt signaling pathway.
Insights
4-Methylumbelliferone (4-MU) shows promise for treating Type 1 diabetes (T1DM) by protecting pancreatic beta cells and improving glucose control. This compound may activate the EGFR/PI3K/Akt pathway, offering a new therapeutic avenue.
Area of Science:
- Endocrinology
- Immunology
- Pharmacology
Background:
- Type 1 diabetes mellitus (T1DM) involves autoimmune destruction of pancreatic beta cells, leading to insulin deficiency.
- Current T1DM treatments manage insulin levels but don't prevent beta cell loss.
- 4-Methylumbelliferone (4-MU), a hyaluronan synthesis inhibitor, has demonstrated anti-inflammatory and cytoprotective properties, but its role in T1DM requires elucidation.
Purpose of the Study:
- To investigate the therapeutic potential and underlying mechanisms of 4-Methylumbelliferone (4-MU) in a mouse model of Type 1 diabetes mellitus (T1DM).
- To assess the effects of 4-MU on beta cell survival, function, and glucose homeostasis in T1DM.
- To explore the molecular pathways targeted by 4-MU in the context of T1DM.
Main Methods:
- Utilized a streptozotocin (STZ)-induced mouse model of T1DM treated with 4-MU.
- Evaluated blood glucose, glucose tolerance, islet morphology, and cell composition.
- Conducted in vitro studies on STZ-injured beta cells to assess viability, oxidative stress, calcium homeostasis, and insulin secretion.
- Employed network pharmacology, molecular docking, qPCR, and Western blot to identify mechanisms.
Main Results:
- 4-MU treatment significantly reduced hyperglycemia and improved glucose tolerance in T1DM mice, preserving beta cell mass and reducing islet inflammation.
- In vitro, 4-MU protected beta cells from STZ-induced damage by mitigating oxidative stress and restoring calcium balance.
- Network pharmacology and molecular docking identified the PI3K/Akt signaling pathway, with 4-MU showing stable binding to key regulators like EGFR and Akt, and enhancing their phosphorylation.
Conclusions:
- 4-Methylumbelliferone (4-MU) demonstrates significant protective effects in Type 1 diabetes mellitus (T1DM).
- 4-MU preserves pancreatic beta cell survival and function, potentially by activating the EGFR/PI3K/Akt signaling pathway.
- These findings suggest 4-MU as a potential therapeutic agent for T1DM.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:26Type I Diabetes II: Pathophysiology
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:24Type II Diabetes II: Pathophysiology